EGFR ACTIVATING MUTATION
Clinical trials for EGFR ACTIVATING MUTATION explained in plain language.
Never miss a new study
Get alerted when new EGFR ACTIVATING MUTATION trials appear
Sign up with your email to follow new studies for EGFR ACTIVATING MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug duo aims to shrink lung tumors before surgery
Disease control Not yet recruitingThis study tests whether giving a high dose of the targeted drug firmonertinib together with bevacizumab before surgery can improve outcomes for people with a specific type of lung cancer (EGFR-mutated, stage II-IIIB). About 62 participants will receive the drug combination, then…
Matched conditions: EGFR ACTIVATING MUTATION
Phase: PHASE2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated May 26, 2026 06:42 UTC
-
AI could help doctors choose the best treatment for lung cancer patients
Knowledge-focused Not yet recruitingThis study looks back at data from 1,000 lung cancer patients with EGFR mutations who received targeted therapy after surgery. Researchers will use artificial intelligence to analyze CT scans, tissue samples, and genetic reports to build a model that predicts treatment success. T…
Matched conditions: EGFR ACTIVATING MUTATION
Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Knowledge-focused
Last updated May 20, 2026 11:56 UTC